Fosteum: Package Insert and Label Information

FOSTEUM — genistein, zinc glycinate citrate and cholecalciferol capsule
Primus Pharmaceuticals, Inc.

Disclaimer: This is a medical food. For further information about medical foods, click here.

DESCRIPTION

FOSTEUM® consists of a specially formulated proprietary blend of high purity genistein aglycone from a natural source, citrated zinc bisglycinate and cholecalciferol (vitamin D3 ). Genistein aglycone reduces osteoclast activity and stimulates osteoblast activity. Citrated zinc bisglycinate works synergistically with genistein aglycone, while both citrated zinc bisglycinate and vitamin D3 also work independently to promote mineralization activity in bone. Vitamin D3 also facilitates calcium absorption from the intestine.

Genistein aglycone

Each FOSTEUM capsule contains 27 mg of genistein aglycone (genistein), derived from a natural source, for a total daily intake of 54 mg. In clinical trials, this level of intake has been shown to increase bone mineral density (BMD). Genistein is chemically described as 4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one. It is the aglycone form of the glucoside isoflavone molecule genistin. The empirical formula of genistein is C15 H10 O5 ; its molecular weight is 270.2. The structural formula is:

Genistein aglycone molecule

Citrated Zinc Bisglycinate

Each FOSTEUM capsule contains 20 mg citrated zinc bisglycinate, a glycine amino acid chelate of zinc formed in the presence of citric acid that provides approximately 4 mg of elemental zinc per capsule. Zinc is an essential mineral co-factor required by enzymes involved in bone metabolism and has important physiological functions in other tissues throughout the body. Elemental zinc has also been shown to have synergistic effects with genistein on bone formation. This zinc bisglycinate, formed in the presence of citric acid, has been shown to have improved absorption over inorganic zinc salts, such as zinc sulfate. Zinc bisglycinate, a chelate of zinc, is complex with an empirical formula of C4 H8 O4 Zn; its molecular weight is 215.5. Its structural formula is:

Citrated zinc bisglycinate molecule


When generated in the presence of citric acid, citrate and additional glycinate ions (not shown) also participate in this structure, forming citrated zinc bisglycinate, contributing to the complexity of the molecule.

Cholecalciferol

Each FOSTEUM capsule contains cholecalciferol equivalent to 200 IU vitamin D3 . Vitamin D3 is the natural form of vitamin D produced when skin is exposed to the sun. Vitamin D is necessary for proper absorption of calcium from the intestine and the use of absorbed calcium in the mineralization of bone. Cholecalciferol is the natural precursor of calcitriol (1,25-dihydroxy-cholecalciferol), the physiologically active form of vitamin D in bone. It is described as (3ßμ,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3-ol. The empirical formula is C27 H44 O; its molecular weight is 384.6. The structural formula is:

Cholcalciferol molecule

Other Ingredients

FOSTEUM contains the following other ingredients as excipients: dicalcium malate, magnesium oxide, micro-crystalline cellulose, magnesium stearate and silicon dioxide in a capsule made from plant sources. FD&C Blue #2 is used for the imprint on the capsule. FOSTEUM does not contain fructose, glucose, sucrose, lactose, gluten, maltodextrin, tree nuts, peanuts, flavors or products of animal or seafood origin. FOSTEUM is suitable for vegans.

Medical Food

Medical Food products are used under a physician’s supervision for the dietary management of diseases in patients with particular medical or metabolic needs due to their disease or condition. The U.S. Congress defined “medical food” in the Orphan Drug Act and Amendments of 1988 as “a food which is formulated to be consumed or administered enterally under the supervision of a physician, and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.” FOSTEUM has been developed, manufactured and labeled in accordance with both the statutory and the FDA regulatory definition of a medical food. FOSTEUM is to be used only under a physician’s supervision.

Generally Recognized As Safe

The ingredients in FOSTEUM are Generally Recognized As Safe (GRAS). This is the statutory safety standard that the U.S. Food and Drug Administration (FDA) requires of all ingredients added to food products. The standard for an ingredient to achieve GRAS status requires technical demonstration of non-toxicity and safety, general recognition of safety through widespread usage and agreement of that safety by experts in the field.

LOW BONE MASS AND OSTEOPOROSIS

Low bone mass (osteopenia) and osteoporosis are gradations of bone loss. Low bone mass may progress to osteoporosis. Low bone mass and osteoporosis occur when the homeostasis of the metabolic processes of normal bone turnover is unbalanced in favor of resorption activity. The World Health Organization (WHO) defines low bone mass as a T-score between -1.0 and -2.5. Osteoporosis is defined at a T-score lower than -2.5.

DIETARY NEED

The highly concentrated, pure form of genistein plus citrated zinc bisglycinate and vitamin D3 in FOSTEUM is specially formulated for the dietary management of the metabolic processes of osteopenia and osteoporosis that cannot be achieved by a change in the normal diet. FOSTEUM provides the distinctive nutrients needed by osteopenic and osteoporotic patients. It restores the metabolic balance of bone turnover toward normal levels.

Epidemiological studies have shown that the risk of osteopenia and osteoporosis in Asian populations is generally 20-30% lower than in Western populations. This lowered risk has been associated with diet, specifically with intake of isoflavones, including genistein, of more than 20 mg per day, and protein from certain legumes of more than 5 g per day. At first glance, it is paradoxical that Asian countries with some of the lowest calcium intakes worldwide have a relatively low rate of osteoporotic hip fractures. Other dietary components, such as isoflavones, may affect the maintenance of bone density in these populations. Isoflavones are found in a variety of natural products. Data exist that support the reduction in bone loss when individuals adopt a diet rich in isoflavones. Moreover, the absence of high isoflavone intake when individuals transition to a more Western style diet results in increased bone loss. Clinical evidence has shown that pure genistein increases bone density in women who have been diagnosed with osteopenia or osteoporosis. Genistein exists in very low concentrations in natural products (generally less than 1%). This amount is not adequate to meet the dietary need of patients with osteopenia or osteoporosis. Concentrating and specially formulating the genistein in FOSTEUM allows the dietary need to be met in a convenient capsule form.

Daily Reference Intake for elemental zinc is 8 mg/day for women and 11 mg/day for men, as established by the Institute of Medicine of the National Academies as published by the National Academy of Sciences (IOM) in 2004. Supplementation with zinc and other minerals has been shown to improve spinal bone mineral density in post-menopausal women. Zinc is an essential co-factor for enzymes involved in the synthesis of bone matrix constituents. As people age, the level of zinc intake generally drops, potentially leading to zinc deficiency and reduced bone quality. Zinc has been shown to act synergistically with the genistein in FOSTEUM to favorably influence bone metabolism.

Vitamin D3 is synthesized in the skin after exposure to UV radiation. A large segment of the American population is vitamin D deficient due to lack of sun exposure or skin aging, especially in northern latitudes and among the elderly who do not produce enough vitamin D3 . In the absence of sufficient vitamin D3 production by the body, the vitamin must be obtained from the diet. Many Americans have inadequate dietary vitamin D intake. Calcitriol, the active form of vitamin D, is required for absorption of calcium from the intestine, regulation of serum calcium, bone formation and bone resorption among other activities.

CLINICAL PHARMACOLOGY

Mechanism of Action

FOSTEUM acts by restoring and maintaining the balance of bone turnover toward normal levels in osteopenia and osteoporosis. Clinical and preclinical data suggest that the genistein in FOSTEUM both reduces osteoclast-mediated bone resorption and stimulates the bone forming activity of osteoblasts. The zinc in FOSTEUM acts synergistically with the genistein, and the cholecalciferol improves the absorption of calcium and its deposition into the mineral matrix of bone.

Osteopenia and osteoporosis generally occur because of hormonal changes associated with the aging process or the use of certain classes of drugs. Bone loss associated with these conditions is primarily due to the metabolic imbalance that occurs when osteoclast activity is greater than osteoblast activity. The imbalance of bone resorption in excess of bone formation is progressive and often leads to fractures. These minimal trauma fractures may lead to significant morbidity and mortality. Successful dietary management of the metabolic processes underlying osteopenia and osteoporosis helps to restore the balance of bone resorption versus bone formation and consequently increases bone density over time.

Genistein aglycone

The genistein in FOSTEUM reduces the activity of osteoclasts and promotes the formation of osteoblasts from progenitor stem cells to increase their number and activity in bone. The net effect is an enhancement of bone formation which restores bone remodeling toward normal levels and results in an increase in bone mineral density (BMD) over time. Through these clinical dietary modifications, FOSTEUM manages the metabolic processes of osteopenia and osteoporosis.

More specifically, preclinical studies suggest the following mechanisms of action: Genistein acts to reverse the effects of estrogen loss by decreasing cytokine production and increasing transforming growth factor ß (TGFß) levels. The net effect is a decrease in receptor activator of nuclear factor kappa B ligand (RANK-L) production, an increase in osteoprotegerin (OPG) levels, and a consequent decrease in overall osteoclast activity. Genistein also increases insulin-like growth factor-1 (IGF-1) leading to an increased number of proto-osteoblasts developed from mesenchymal stem cells. Genistein restores endothelial cell signals resulting in increased recruitment of these precursor cells to form osteoblasts. Genistein also reverses early apoptosis of osteoblasts. These actions likely produce a net increase in osteoblast activity and concomitant decrease in osteoclast activity.

In clinical trials, the genistein in FOSTEUM decreased urinary levels of the bone resorption markers deoxypyridinoline (DPYR) and pyridinoline (PYR), and increased serum levels of the bone formation markers bone-specific alkaline phosphatase (BAP), osteocalcin (OC), and IGF-1. These data suggest that genistein increases BMD over time by decreasing bone resorption and increasing bone formation.

Zinc (Elemental)

Studies have shown that zinc has a positive effect on bone formation. The zinc in FOSTEUM is the citrated bisglycinate form, which has been shown to have improved absorption from the intestine compared to inorganic zinc salts.

Cell cultures of rat femoral-metaphyseal tissue treated with zinc and genistein produced a greater increase in BAP, DNA and bone calcium content compared with either agent alone. Other studies have demonstrated that genistein and zinc produce synergistic effects on osteoclast apoptosis and bone mineralization. Animal studies support these findings by showing that the combination of zinc and genistein increases mineralization in bone over genistein alone. In both men and women, zinc was shown to potentiate the effect of high genistein-containing fermented food on bone markers by further increasing the levels of BAP and OC. Based on these data, genistein and zinc increase osteoblast activity while decreasing osteoclast activity to a greater extent than either genistein or zinc alone.

Cholecalciferol

The physiologically active form of vitamin D, calcitriol, regulates calcium and phosphate absorption and modulates serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption. Vitamin D deficiency is associated with a negative calcium balance, increased parathyroid hormone levels, bone loss and increased risk of skeletal fracture. Severe deficiency results in hyperparathyroidism, hypophosphatemia, bone loss, proximal muscle weakness and osteomalacia.

METABOLISM

Genistein

The genistein in FOSTEUM is freely absorbed in the gut, where it is at least partly converted to one metabolite, 7-O-beta-glucuronide, before it crosses the mucosa from the intestinal lumen. In hepatic first pass metabolism, genistein is converted via a two-stage process involving initial CYP450-mediated hydroxylation, followed by glucuronidation and sulfonation to the principal conjugated circulating metabolites. Genistein metabolites are converted back into the aglycone form in a variety of tissues. The aglycone is believed to be the principal active form, but conjugates have shown some activity in estrogen-receptor binding assays. Genistein and its conjugates are excreted via urine and bile.

Citrated zinc bisglycinate

Citrated zinc bisglycinate consists of zinc chelated by glycine in the presence of citric acid. Once absorbed, the zinc is released from the chelate. Subsequently, glycine is utilized in normal protein metabolism and zinc is bound to albumin as well as blood cells and distributed throughout the body. The citrate is absorbed and utilized in the tricarboxylic acid cycle (Krebs cycle). The majority of zinc in the human body is found in muscle and bone. Excretion occurs predominantly via the feces.

Cholecalciferol

Ultraviolet light acts on 7-dehydrocholesterol (provitamin D3 ) in skin, where it is converted to 9,10-secosterol (previtamin D3 ). Previtamin D3 is converted into 25-hydroxycholecalciferol in the liver by the P450 enzyme CYP27. This molecule is further converted in the kidney by the P450 enzyme CYP27B1 to the active hormone 1,25-dihydroxycholecalciferol (calcitriol).

CLINICAL EXPERIENCE

Hepatic and Renal Effects

In clinical studies, the effects of genistein in FOSTEUM on blood chemical, hepatic and renal functional measures were compared in post-menopausal subjects receiving genistein plus calcium carbonate (calcium) and vitamin D3 with post-menopausal, age-matched subjects receiving only calcium and vitamin D3 . No changes were noted over a three year period in either group and all measures remained within normal limits.

Since the precursor form of vitamin D3 is transformed to the active form in the liver and then kidney, it is expected that patients with severe liver or kidney impairment may not transform the vitamin adequately.

Effects on Reproductive Tissues

Effects of the genistein in FOSTEUM on breast density, vaginal cytology and endometrial thickness were tested in double-blind, placebo-controlled clinical trials. One trial with 30 post-menopausal subjects in each arm found that genistein did not affect endometrial thickness over a one year period compared to placebo. In other controlled trials, daily administration of 54 mg of genistein over one, two and three year periods produced no increases in endometrial thickness or breast density in post-menopausal women. Furthermore, a subset of 113 post-menopausal women showed no change in vaginal cytology following one year of daily genistein therapy. These data suggest that the genistein in FOSTEUM does not produce adverse estrogenic effects in reproductive tissues.

Cardiovascular Safety

In a study of 60 post-menopausal subjects comparing the cardiovascular markers of those receiving the genistein in FOSTEUM to a matched group receiving placebo, homocysteine and C-reactive protein (CRP) were assessed at baseline and again at 6 months. No statistically significant differences were seen between groups. Soluble intercellular adhesion molecule-1 (iCAM), vascular cell adhesion molecule-1 (vCAM), fibrinogen and F2-isoprostane levels were assessed at baseline and again at 12 and 24 months in 389 post-menopausal subjects randomized to receive either genistein, calcium and vitamin D3 or calcium and vitamin D3 only (placebo). At both 12 and 24 months, the levels of all four cardiovascular markers were reduced in the genistein group compared to both baseline and placebo at all time points. No significant changes in lipid profile were observed in either the genistein or placebo group over the course of the study. These data indicate that genistein does not adversely affect markers of cardiovascular risk. An additional study of 53 post-menopausal women measured changes in flow-mediated vasodilation and plasma nitric oxide status. The genistein in FOSTEUM significantly increased plasma nitrite/nitrate levels and reduced levels of endothelin-1 compared to placebo. After 12 months of use, forearm blood flow increased significantly during reactive hyperemia in the genistein group compared to placebo. Flow-mediated dilation in the proximal and distal brachial arteries both increased significantly after genistein administration. The purified genistein in FOSTEUM improved endothelial function in a cohort of post-menopausal women.

Page 1 of 3 1 2 3

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2022. All Rights Reserved.